📊 KURA Key Takeaways
Is Kura Oncology, Inc. (KURA) a Good Investment?
Kura Oncology demonstrates encouraging 25.2% revenue growth and maintains a fortress balance sheet with excellent liquidity (6.06x current ratio) and minimal debt. However, the company faces substantial operational losses (-$303.6M) and annual cash burn of -$70.7M, requiring successful pipeline advancement and commercialization to reach profitability within its ~2-year cash runway.
Kura Oncology exhibits strong liquidity and low leverage, but fundamentals reflect an early-stage profile with severe, widening losses and deeply negative returns. Despite 25% YoY revenue growth, operating and net margins are extremely negative and free cash flow is materially negative, implying continued cash burn. Without clear progress toward sustainable revenue and margin improvement, risk dominates on fundamentals.
Why Buy Kura Oncology, Inc. Stock? KURA Key Strengths
- Strong revenue growth of 25.2% YoY despite pre-profitability stage
- Excellent liquidity position with 6.06x current ratio and $149.1M cash reserves
- Minimal leverage with 0.06x debt-to-equity ratio and only $9.7M long-term debt
- Generating meaningful revenue ($67.5M) indicating product commercialization progress
- Strong liquidity with 6.06x current ratio and sizable cash
- Low leverage (0.06x D/E; minimal long-term debt)
- Double-digit YoY revenue growth indicating some traction
KURA Stock Risks: Kura Oncology, Inc. Investment Risks
- Severe negative profitability with -449.9% operating margin and -$278.7M net loss
- Annual free cash flow burn of -$70.7M limiting runway to approximately 2 years at current rates
- Operating losses of $303.6M far exceed revenue, indicating inability to cover costs from sales alone
- Success dependent on clinical trial outcomes and regulatory approvals outside scope of current financial data
- Severe unprofitability with deeply negative margins and ROE/ROA
- Persistent negative free cash flow implying potential future financing needs
- Revenue quality risk (potentially nonrecurring milestones) and thin equity vs liabilities
Key Metrics to Watch
- Revenue growth trajectory and gross margin expansion as products scale
- Operating cash burn rate reduction and path to cash flow breakeven
- Clinical pipeline advancement and regulatory approval timeline
- Ability to achieve profitability or adequacy of capital before requiring additional fundraising
- Operating cash burn and cash runway (OCF vs cash balance)
- Operating margin improvement toward breakeven
Kura Oncology, Inc. (KURA) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 6.06x current ratio provides a solid financial cushion.
KURA Profit Margin, ROE & Profitability Analysis
KURA vs Healthcare Sector: How Kura Oncology, Inc. Compares
How Kura Oncology, Inc. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Kura Oncology, Inc. Stock Overvalued? KURA Valuation Analysis 2026
Based on fundamental analysis, Kura Oncology, Inc. has mixed fundamental signals relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Kura Oncology, Inc. Balance Sheet: KURA Debt, Cash & Liquidity
KURA Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Kura Oncology, Inc.'s revenue has grown significantly by 25% over the 5-year period, indicating strong business expansion. The most recent EPS of $-2.08 indicates the company is currently unprofitable.
KURA Revenue Growth, EPS Growth & YoY Performance
KURA Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2025 | $20.8M | -$49.5M | $-0.63 |
| Q2 2025 | $15.3M | -$49.5M | $-0.59 |
| Q1 2025 | $14.1M | -$49.5M | $-0.59 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Kura Oncology, Inc. Dividends, Buybacks & Capital Allocation
KURA SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Kura Oncology, Inc. (CIK: 0001422143)
📋 Recent SEC Filings
❓ Frequently Asked Questions about KURA
What is the AI rating for KURA?
Kura Oncology, Inc. (KURA) has a Combined AI Rating of SELL from Claude (HOLD) and ChatGPT (SELL) with 69% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are KURA's key strengths?
Claude: Strong revenue growth of 25.2% YoY despite pre-profitability stage. Excellent liquidity position with 6.06x current ratio and $149.1M cash reserves. ChatGPT: Strong liquidity with 6.06x current ratio and sizable cash. Low leverage (0.06x D/E; minimal long-term debt).
What are the risks of investing in KURA?
Claude: Severe negative profitability with -449.9% operating margin and -$278.7M net loss. Annual free cash flow burn of -$70.7M limiting runway to approximately 2 years at current rates. ChatGPT: Severe unprofitability with deeply negative margins and ROE/ROA. Persistent negative free cash flow implying potential future financing needs.
What is KURA's revenue and growth?
Kura Oncology, Inc. reported revenue of $67.5M.
Does KURA pay dividends?
Kura Oncology, Inc. does not currently pay dividends.
Where can I find KURA SEC filings?
Official SEC filings for Kura Oncology, Inc. (CIK: 0001422143) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is KURA's EPS?
Kura Oncology, Inc. has a diluted EPS of $-3.18.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is KURA a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Kura Oncology, Inc. has a SELL rating with 69% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is KURA stock overvalued or undervalued?
Valuation metrics for KURA: ROE of -160.0% (sector avg: 15%), net margin of -412.9% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy KURA stock in 2026?
Our dual AI analysis gives Kura Oncology, Inc. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is KURA's free cash flow?
Kura Oncology, Inc.'s operating cash flow is $-64.1M, with capital expenditures of $6.6M. FCF margin is -104.8%.
How does KURA compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -412.9% (avg: 12%), ROE -160.0% (avg: 15%), current ratio 6.06 (avg: 2).